Back to today’s briefing

Story perspectives

Breakthrough Therapy Shrinks Tumors in Head and Neck Cancer

10/29/2025

41 3

Summary

Story summary

In a large clinical trial across 11 countries, amivantamab shrinks tumors within six weeks and slows progression in metastatic head and neck squamous cell carcinoma (HNSCC).
Kevin Harrington, professor at the Institute of Cancer Research, says the triple-action therapy could significantly change treatment approaches.
Findings were presented at the European Society for Medical Oncology conference in Berlin.

1 of 1

Story summary

In a large clinical trial across 11 countries, amivantamab shrinks tumors within six weeks and slows progression in metastatic head and neck squamous cell carcinoma (HNSCC).
Kevin Harrington, professor at the Institute of Cancer Research, says the triple-action therapy could significantly change treatment approaches.
Findings were presented at the European Society for Medical Oncology conference in Berlin.